Zaleplon can be addictive, but it carries a lower risk of dependence than most other prescription sleep medications. The federal government classifies it as a Schedule IV controlled substance, meaning it has a recognized potential for abuse, though that potential is considered relatively low. Its ultrashort duration of action (it’s eliminated from the body faster than nearly any other sleep aid) is one reason it’s less likely to lead to dependence than longer-acting alternatives.
How Zaleplon Affects the Brain
Zaleplon belongs to a class of drugs sometimes called “Z-drugs,” which work on the same brain receptors as benzodiazepines but in a more targeted way. It selectively activates a specific subtype of the GABA receptor system, the one most closely tied to inducing sleep. Benzodiazepines, by contrast, activate multiple subtypes, which is why they produce broader effects like muscle relaxation, anxiety relief, and sedation all at once. That broader activation also contributes to a higher risk of dependence.
Because zaleplon is so selective in what it targets, it produces fewer of the rewarding, euphoric effects that typically drive addiction. It essentially nudges you toward sleep without producing the full-body relaxation that makes benzodiazepines feel pleasurable to misuse. That said, at higher-than-prescribed doses, zaleplon can produce euphoria, which is why abuse remains possible.
Tolerance and How Quickly It Develops
One hallmark of addiction is tolerance: needing more of a drug over time to get the same effect. In clinical trials lasting up to five weeks, zaleplon showed no measurable tolerance development. Patients taking it nightly fell asleep just as quickly on week four or five as they did on night one, without needing a higher dose. This is notably different from benzodiazepines, where tolerance to the sleep-inducing effects can emerge within days to weeks.
That said, the FDA notes that zaleplon’s benefits have only been studied for periods up to about four weeks. Whether tolerance might develop with longer use remains an open question, which is one reason zaleplon is approved only for short-term treatment of insomnia.
Zaleplon vs. Other Sleep Medications
Compared to benzodiazepines, zaleplon and the other Z-drugs (zolpidem and zopiclone) are consistently associated with lower abuse potential. Benzodiazepines have been more definitively linked to physiological dependence, withdrawal syndromes, and dose escalation over time. The Z-drugs, as a group, are less likely to cause tolerance, produce milder withdrawal effects, rarely cause rebound insomnia, and have fewer impacts on daytime performance and memory.
Even within the Z-drug class, zaleplon appears to sit at the lower end of the risk spectrum. Its half-life is roughly one hour, compared to about two to three hours for zolpidem. That means it’s in and out of your system quickly, leaving less time for the brain to “learn” the rewarding effects that fuel dependence. Most reported cases of Z-drug abuse have involved zolpidem rather than zaleplon, though both carry some risk, particularly in people with a history of substance use disorders.
What Happens When You Stop Taking It
Zaleplon can cause rebound insomnia, a temporary worsening of sleep difficulty after you stop taking it. This happens because the brain adjusts to the drug’s presence and then overshoots when the drug is removed. Rebound insomnia from zaleplon is generally mild and short-lived, resolving once the drug fully clears your system. Because zaleplon is eliminated so quickly, this rebound period tends to be brief.
Physical withdrawal symptoms, the kind associated with benzodiazepine dependence (anxiety, tremors, sweating, seizures in severe cases), are uncommon with zaleplon at prescribed doses. They become more likely if someone has been taking higher doses than prescribed or using the drug for an extended period. People with a prior history of alcohol or drug dependence are at elevated risk for developing problematic use patterns with any sleep medication, including zaleplon.
Recommended Duration of Use
Zaleplon is approved for short-term treatment of insomnia only. The FDA recommends reassessing if sleep problems haven’t improved within 7 to 10 days, as persistent insomnia may signal an underlying medical or psychiatric condition rather than a standalone sleep problem. This short treatment window exists partly to minimize dependence risk and partly because the drug hasn’t been proven effective beyond about four weeks of nightly use.
If you’ve been taking zaleplon regularly for more than a few weeks, tapering off gradually rather than stopping abruptly can reduce the chance of rebound insomnia. Your prescriber can help adjust the timeline based on how long you’ve been using it and at what dose.
Who Faces Higher Risk
The people most likely to develop a problematic relationship with zaleplon are those with a current or past history of substance use disorders. In clinical reports of Z-drug abuse, patients frequently had prior alcohol or drug dependence. If that applies to you, it’s worth discussing alternative approaches to insomnia, including cognitive behavioral therapy for insomnia, which is considered the first-line treatment and carries no dependence risk at all.
Taking zaleplon at doses higher than prescribed, using it recreationally, or combining it with alcohol or other sedatives also significantly increases both the risk of addiction and the risk of dangerous side effects. At prescribed doses and for the recommended duration, most people use zaleplon without developing dependence.